CD274 and non-small cell lung carcinoma: To date, the utilisation of anti-PD-1/PD-L1 ICI alongside novel ICI agents (e.g., targeting LAG-3, TIM-3, TIGIT, and VISTA)—whilst demonstrating synergistic antitumour responses in preclinical studies and early phase clinical trials—have yet to demonstrate improved outcomes in randomised trials of non-selected NSCLC populations.